References
- Harding M J, Cantwell B MJ, Milstead R AV, et al. Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8- dideazafolic acid) in colorectal cancer. Br J Cancer 1988; 57: 628–629
- Cantwell B MJ, Macaulay V, Harris A L, et al. Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB3717) in advanced breast cancer. Eur J Cancer Clin Oncol 1988; 24: 733–736
- Cantwell B MJ, Earnshaw M, Harris A L. Phase II study of a novel antifolate, N10-propargyl-5,8-dideazafolic acid (CB3717), in ma- lignant mesothelioma. Cancer Treat Rep 1986; 70: 1335–1336
- Bassendine M F, Curtin N J, Loose H, et al. Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study. J Hepatol 1987; 4: 349–356
- Cantwell B MJ, Harris A L. The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8-dideazafolic acid). Br J Cancer 1988; 58: 189–190
- Galivan J, Nimec Z, Rhee M. Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine. Cancer Res 1987; 47: 5256–5260